HI
REGN icon

Honeywell International’s Regeneron Pharmaceuticals REGN Stock Holding History

Honeywell International’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-33,000
Closed -$12.8M – 204
2017
Q1 		$12.8M Buy
+33,000
New +$12.2M 0.41% 97

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

Honeywell International's REGN Position: Q2 2017 in Review

Honeywell International sold out of Regeneron Pharmaceuticals (REGN) in Q2 2017, closing a stake of 33,000 shares — an estimated $12.8M sold.

Honeywell International first reported a position in REGN in Q1 2017 and held it in 1 quarter. The position peaked at $12.8M in Q1 2017. 603 funds tracked by Wall St. Rank hold REGN as of Q2 2017.

  • Honeywell International reported no remaining Regeneron Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Honeywell International sold 33,000 Regeneron Pharmaceuticals shares in Q2 2017, an estimated $12.8M.
  • Honeywell International first reported a position in Regeneron Pharmaceuticals in Q1 2017 and held it in 1 quarter.
  • Honeywell International's Regeneron Pharmaceuticals position peaked at $12.8M in Q1 2017.
  • 603 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2017.

Based on Honeywell International's 13F filing for Q2 2017, filed 31 Jul 2017.